Table 2 Best response by RECIST 1.1.

From: Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

Response

Number of patients (%)

Confirmed PR

1 (6)

SD

14 (78)

PD

2 (11)

Not evaluable

1 (6)

CBR (CR + PR + SD ≥ 24 weeks)

3 (17)

  1. CBR clinical benefit rate = CR + PR + SD ≥ 24 weeks, CR complete response, PR partial response, SD stable disease.
Back to article page